Technical briefing 9 This briefing provides an update on previous briefings up to 1 April 2021 Summary • There are 4 variants of concern and 7 variants under investigation (Table 1). VOC-20DEC-01 (B.1.1.7) remains predominant in the UK. Other variants of concern and variants under investigation remain a very low proportion of the available sequence […]
Category Archives: diagnostic article
Technical briefing 8 This briefing provides an update on previous briefings up to 11 March 2021 Summary • There are 4 variants of concern and 6 variants under investigation (Table 1). Definitions for variants of concern, variants under investigation and signals in monitoring have been updated. VOC-20DEC-01 (B.1.1.7) remains predominant. Other variants of concern and […]
Variant of Concern 2021/03 Technical briefing 7 This briefing provides an update on previous briefings up to 13 February 2021 Summary • There are 4 variants of concern and 5 variants under investigation (Table 1) • A slightly increased risk of hospitalisation has been now been detected for VOC 202012/01 (B.1.1.7), supporting previous findings on […]
Variant of Concern 202012/01Technical briefing 6 This briefing provides an update on previous briefings up to 1 February 2021 Summary There are 4 variants of concern, designated: • VOC 202012/01 (B.1.1.7), first detected in Kent England is predominant in all regions and is circulating in multiple countries• VOC 202102/02 (B.1.1.7 cluster with E484K mutation), first detected in South West […]
Variant of Concern 202012/01Technical briefing 5 This briefing provides an update on the briefing of 14 January 2021 Summary SGTF detections indicate VOC202012/01 continues to predominate across all regions. S gene target failure remains a well correlated proxy measure of VOC 202012/01. An assessment of severity of disease has been conducted by NERVTAG. A limited […]
Variant of Concern 202012/01 Technical briefing 4 This briefing provides an update on the briefing of 8 January 2021 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, […]
Variant of Concern 202012/01Technical briefing 3 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following risk assessment with the relevant expert committee, they may […]
137 candidate vaccines in clinical evaluation ID Vaccine platform acronym Vaccine platform description Type of candidate vaccine Route of administration Developers Phase Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 1 IV Inactivated virus CoronaVac; SARS-CoV-2 vaccine (inactivated) IM Sinovac Research and Development Co., Ltd Phase 4 NCT04383574 NCT04754698** NCT04456595 NCT04756830 […]
Guangdi Li1 and Erik De Clercq2 1 Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China. 2 Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. https://doi.org/10.1038/d41573-020-00016-0 Supplementary Table 1 | Summary of antiviral compounds against human coronaviruses Virus-based treatment strategies 2019-nCoV;Influenza RdRp Favipiravir […]
A new variant of the virus that causes COVID-19 (SARS-CoV-2) has been identified across the South East of England. The variant was identified due to Public Health England’s (PHE) proactive and enhanced monitoring following the increase in cases seen in Kent and London. The variant has been named ‘VUI – 202012/01’ (the first Variant Under Investigation […]
